Table 3.
Clinical factors associated with adverse events to risperidone
| Variable | OR (95% CI) for AEa | |
|---|---|---|
| Unadjustedb | Adjustedc | |
| Indications | ||
| Self-injurious behaviors (present vs. absent) | 3.76 (2.18–6.49) | 3.06 (1.72–5.44) |
| Aggression (present vs. absent) | 1.67 (1.06–2.61) | 1.15 (0.70–1.88) |
| Irritability (present vs. absent) | 1.72 (1.03–2.86) | 1.44 (0.82–2.52) |
| Presence of comorbidity (present vs. absent) | 1.14 (0.72–1.80) | 1.20 (0.73–1.97) |
| Age at commencing risperidone (each additional year) | 1.02 (0.97–1.06) | 1.02 (0.99–1.07) |
| Risperidone dosing regimen | ||
| Starting dose of risperidone (per additional mg/day) | 1.05 (0.84–1.30) | 1.01 (0.80–1.27) |
| Starting dosing frequency of risperidone (single vs. multiple dosing) | 1.15 (0.90–1.47) | 1.28 (0.98–1.68) |
| Risperidone dose increase (present vs. absent) | 1.38 (0.84–2.26) | 1.22 (0.68–2.16) |
| Concomitant medicines | ||
| Analgesics (present vs. absent) | 0.29 (0.12–0.69) | 0.44 (0.16–1.14) |
| Antibiotics (present vs. absent) | 0.13 (0.03–0.56) | 0.20 (0.05–0.94) |
| Orexigenics (present vs. absent) | 0.72 (0.36–1.40) | 1.01 (0.49–2.06) |
Significant associations are in bold
AE adverse event, CI confidence interval, OR odds ratio
aThe model was generated using binary logistic regression
bUnadjusted OR refers to the OR for each variable with no others in the model
cAdjusted OR refers to the OR after all variables were included in the model